Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1999

View Archived Issues

Priority review status assigned to Rapamune immunosuppressive therapy

Pediatric use of Maxipime approved by the FDA

Roberts and Yuhan enter distribution agreement for Agrylin in Korea

Alza launches Ditropan XL in the U.S.

GABA-A ligands useful for treating CNS disorders

Tachykinin antagonists claimed by HMR for asthma, cough, bronchitis and pain

New series of NHE inhibitors in development at Synthelabo

Enzon initiates phase III trials of PEG-Intron/Rebetol combination therapy for hepatitis C

Improved salts of ACE inhibitors prepared at NicOx

Bayer describes production and use of 2,9-disubstituted purin-6-ones

Schering discloses new leukotriene antagonists particularly useful as dermatological products

Genetics Kenkyusho and Yamanouchi to continue development of joint venture products separately

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Kirin to restart clinical trials of TPO

Clinical trials for Japanese immunosuppressant begin in Europe

KRH-594, a new angiotensin antagonist, evaluated in animal models of hypertension

Genome Therapeutics achieves milestone in asthma alliance with Schering-Plough

Cantab completes acquisition of drug addiction programs from ImmuLogic

New immunomodulator LK-423 possesses unique pharmacological properties

Boehringer Ingelheim seeks E.U. marketing approval for non-CFC respiratory device

Cephalon's narcolepsy treatment launched in Ireland

Moderate drinking reported to protect against ischemic stroke

Ontogen completes phase I study of MDR-modulating compound

Ontogeny enters diabetes research collaboration with Becton Dickinson

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...